Epigenetic therapy shows promise in hard-to-treat lung cancer

Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new epigenetic therapy may have potential for this population, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

Read the whole article on Physorg

More from Physorg